Stay updated on Amivantamab & Lazertinib in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Amivantamab & Lazertinib in NSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-19T14:09:41.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-12T14:47:54.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study record content. The visible elements indicate an access block preventing viewing trial details.
    Difference
    19%
    Check dated 2026-09-21T20:38:13.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    The page revision tag was updated from v3.6.5 to v3.6.6, indicating a minor update to the study record.
    Difference
    0.1%
    Check dated 2026-08-31T17:33:23.000Z thumbnail image
  6. Check
    76 days ago
    Change Detected
    Summary
    The page now shows a 500-style error page with an HTML structure indicating the requested study record is temporarily unavailable.
    Difference
    18%
    Check dated 2026-08-10T11:50:42.000Z thumbnail image
  7. Check
    90 days ago
    Change Detected
    Summary
    Footer revision label updated from Revision: v3.6.3 to Revision: v3.6.4, indicating a minor site update that does not alter the study information.
    Difference
    0.1%
    Check dated 2026-07-27T05:53:11.000Z thumbnail image

Stay in the know with updates to Amivantamab & Lazertinib in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.